DRUG RESISTANCE IN PEOPLE FAILING DOLUTEGRAVIR-BASED ART: HIV COHORT COLLABORATION
Background: In 2019, the World Health Organization (WHO) recommended dolutegravir (DTG) as the preferred drug for first- and second-line antiretroviral therapy (ART) among all people with HIV (PWH), including pregnant women and those of childbearing age. DTG has a high genetic barrier to resistance, but PWH with resistance to nucleoside reverse-transcriptase inhibitors (NRTIs) who are…